Luspatercept Lowers the Transfusion Burden in Patients With Myelofibrosis-Associated Anemia
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.
Aaron Gerds, MD, assistant professor of Medicine, Cleveland Clinic - Taussig Cancer Center, discussed the results of a phase II BELIEVE study of luspatercept (Reblozyl) as treatment of patients with myelofibrosis-associated anemia.
Every cohort in the study had responses to treatment with luspatercept. Additionally, luspatercept successfully reduced the transfusion burden in 21.4% of the study subjects compared only 4.5% of those who received placebo, meeting the primary end point of the study.
Gerd notes, however, that responses were higher in patients who received ruxolitinib (Jakafi) along with the luspatercept.
<< View more content from the 2019 American Society of Hematology Annual Meeting
